PetrichorCapital Partners
PetrichorCapital Partners
Provides structured growth capital to facilitate the adoption of healthcare innovations
Petrichor Capital Partners makes structured investments across the global healthcare sector, with a focus on biopharmaceuticals, medical technology, diagnostics/tools, and tech-enabled services.
We provide growth investment solutions for late and commercial-stage companies.
We work with both public and private companies to support their long-term growth efforts and have deep experience with acquisitions, research & development activities, and commercial launches or expansions, among other situations.
Our investments enable leading healthcare innovators to reach the next stage of their evolution. Petrichor acts as a strategic advisor, partnering with management, Boards, and other investors to help ensure the success of our companies.
Petrichor Capital Partners in practice
Flexible Structures
Debt, equity and other structures tailored to a company’s needs.
High Growth Companies
Focused on late-stage or commercial public or private biopharma, medtech, and diagnostics companies, among others, providing capital for growth, M&A, and/or product development or launch, and beyond.
Enabling Long-Term Growth
Petrichor serves as value-added partner to execute long-term strategic vision.
Meet the team
The team has led over 125 investments, representing more than $6 billion of invested capital, and has sat on over 55 boards.
Meet the team
Portfolio
Discover the incredible companies that make up the Petrichor Capital Partners fund.
View portfolio
News
Read all newsPalvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
January 2025
Read more on 
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
January 2025
Read more on
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
January 2025
Read more on
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
December 2024
Read more on
Aurion Biotech Announces Positive Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction
December 2024
Read more on
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
December 2024
Read more on